Potency of Lianhua Qingwen granule combined with paramivir sodium chloride injection in treating influenza and level changes of serum inflammatory factors

Objective: To evaluate the therapeutic efficacy and serum inflammatory factors changes of influenza patients received Lianhua Qingwen granule combined with peramivir sodium chloride injection.

Methods: The clinical data of 100 influenza patients enrolled in our infirmary from January 2018 to January 2020 were retrospectively analyzed.

Among them, 50 patients received eramivir sodium chloride injection (the control group) and 50 patients received Lianhua Qingwen granule plus (the experimental group).

The clinical efficacy and serum inflammatory factor, including C-reactive protein (CRP), interleukin (IL)-6, and procalcitonin (PCT) were recorded and compared.

Results: The overall effective rate of the experimental group was significantly higher than that of the control group (96.0% vs. 80%, P=0.014).

There was difference in the antipyretic time, sore throat relief time, cough relief time and general ache relief time between the two groups (all P < 0.05).

Before treatment, there was no difference in IL-6, CRP, and PCT levels between the two groups (all P > 0.05).

After treatment, the IL-6, CRP, and PCT levels were decreased in the two groups, and lower in the experimental group compared with the control group (all P=0.014).

The ADRs rate in the experimental group was significantly lower than that of the control group (6.0% vs. 24%, χ(2)=6.353, P=0.012).

Conclusion: Lianhua Qingwen granule combined with peramivir sodium chloride injection shows a remarkable potency in influenza patients.

It can reduce the treatment span and improve the inflammatory factors, which is worthy of clinical promotion and application.